Die wichtigsten Arbeiten zu.....
Efavirenz (Sustiva®)
# 59LB ACTG 5202: Final Results of ABC/3TC or TDF/FTC with either EFV or ATV/r in Treatment-naive HIV-infected Patients
Eric Daar*1, C Tierney2, M Fischl3, A Collier4, K
Mollan2, C Budhathoki2, C Godfrey5, N Jahed6, D Katzenstein7, P
Sax8, and ACTG A5202 Study Team
1Los Angeles Biomed Res Inst at Harbor-UCLA, Torrance, US;
2Harvard Sch of Publ Hlth, Boston, MA, US; 3Univ of Miami Miller Sch of Med, FL, US;
4Harborview Med Ctr, Univ of Washington, Seattle, US; 5Div of AIDS, NIH, Bethesda, MD, US;
6Social & Sci Systems, Inc, Silver Spring, MD, US; 7Stanford Univ, CA, US; and
8Brigham and Women`s Hosp, Harvard Med Sch, Boston, MA, US
#106LB Bone and Limb Fat Outcomes of ACTG A5224s, a Substudy of ACTG A5202: A Prospective, Randomized, Partially Blinded Phase III Trial of ABC/3TC or TDF/FTC with EFV or ATV/r for Initial Treatment of HIV-1 Infection
Grace McComsey*1, D Kitch2, E Daar3, C Tierney2, N Jahed4, P Tebas5, L Myers6, P Sax7, and AACTG
Study A5224
1Case Western Reserve Univ, Cleveland, OH, US; 2Harvard Sch of Publ Hlth, Boston, MA, US; 3Los Angeles
Biomed Res Inst at Harbor-UCLA, Torrance, US; 4Social & Sci Systems, Inc, Silver Spring, MD, US; 5Univ of
Pennsylvania, Philadelphia, US; 6Frontier Sci and Tech Res Fndn, Amherst, NY, US; and 7Brigham and Women`s Hosp, Harvard
Med Sch, Boston, MA, US
#510 A One-pill, Once-daily Fixed-dose Combination of Efavirenz, Emcitrabine, and Tenofovir Disoproxil Fumarate Regimen Is Associated with Higher Unannounced Pill Count Adherence than Non-one-pill, Once-daily Regimens
David Bangsberg*1, K Ragland2, A Monk2, and S Deeks2
1Massachusetts Gen Hosp, Harvard Med Sch,
Boston, US and 2Univ of California, San Francisco, U
#720 Metabolic Profiles and Body Composition Changes in Treatment-Naive HIV-Infected Patients Treated with Raltegravir 400 mg Twice-daily vs Efavirenz 600 mg Each bedtime Combination Therapy: 96-Week Follow-Up
Edwin DeJesus*1, C Cohen2, J Lennox3, A Lazzarin4, D Berger5, B Jin6, H Teppler6, B-Y Nguyen6, R
Leavitt6, and P Sklar6
1Orlando Immunology Ctr, FL, US; 2Community Res Initiative of New England, Boston, MA, US;
3Emory Univ, Atlanta, GA, US; 4Univ Vita-Salute San Raffaele, Milan, Italy; 5Northstar Med Ctr, Chicago, IL, US; and
6Merck Res Labs, North Wales, PA, US
